Elevated gingival crevicular fluid asprosin levels associate with advanced periodontitis severity
Background
Periodontitis is a chronic inflammatory disease affecting the supporting structures of teeth, leading to gingival inflammation, bone loss, and ultimately tooth loss. Current diagnostic methods primarily rely on clinical parameters like probing depth (PD) and clinical attachment loss (CAL), which indicate past tissue destruction rather than active disease. There is a critical need for non-invasive, early biomarkers to detect disease progression and severity. Gingival crevicular fluid (GCF), a serum transudate, offers a rich source of local inflammatory mediators and systemic hormones, making it an ideal medium for identifying such biomarkers. Investigating novel metabolic hormones like asprosin, adropin, and irisin in GCF could provide new insights into periodontal pathogenesis and health.
Study Design
Researchers conducted a cross-sectional study with a total of 122 systemically healthy participants, aged 25-60 years, divided into four groups: healthy periodontium (n=30), gingivitis (n=30), Stage I-II periodontitis (n=32), and Stage III-IV periodontitis (n=30). Clinical periodontal parameters including probing depth (PD), clinical attachment loss (CAL), bleeding on probing (BOP), plaque index (PI), and gingival index (GI) were recorded. GCF samples were collected from each participant, and the levels of asprosin, adropin, and irisin were quantified using ELISA assays. Statistical analyses involved ANOVA/Kruskal-Wallis with post hoc tests, Pearson correlations, and receiver operating characteristic (ROC) analysis to assess diagnostic potential.
Results
The study revealed significant differences in GCF hormone levels across periodontal statuses. Asprosin levels were notably higher in the Stage III-IV periodontitis group compared to all other groups, with a statistically significant difference (p < 0.05). Conversely, adropin and irisin levels tended to be higher in the healthy periodontium group, although these differences did not reach statistical significance. Correlation analyses showed that asprosin levels positively correlated with several key clinical parameters: plaque index (PI), probing depth (PD), clinical attachment loss (CAL), and bleeding on probing (BOP). In contrast, irisin levels exhibited a negative correlation with plaque index (PI).
Key Findings
- GCF asprosin levels were significantly higher in Stage III-IV periodontitis compared to other groups (p < 0.05).
- Asprosin levels positively correlated with
plaque index (PI),probing depth (PD),clinical attachment loss (CAL), andbleeding on probing (BOP). - Adropin and irisin levels were higher in the healthy periodontium group, though not statistically significant.
- Irisin levels negatively correlated with
plaque index (PI). - ROC analysis indicated asprosin's diagnostic potential for distinguishing advanced periodontitis.
Why It Matters
This study provides novel insights into the potential utility of metabolic hormones as biomarkers for periodontal health and disease. Elevated GCF asprosin levels could serve as a non-invasive indicator of advanced periodontitis severity, potentially aiding in earlier diagnosis or monitoring treatment efficacy. For clinicians, this suggests a future where GCF analysis might complement traditional clinical assessments, allowing for more precise, personalized management of periodontal disease. While more research is needed to establish causality and develop a clinical protocol, these findings open avenues for exploring asprosin as a prognostic marker or even a therapeutic target. The association of adropin and irisin with periodontal health also highlights their potential protective roles, warranting further investigation into their mechanisms and possible use in preventive strategies or adjunctive therapies.
asprosin
adropin
irisin
periodontitis
gingivitis
biomarker